Hemoglobinuria

Denver, CO, July 14, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Paroxysmal Nocturnal Hemoglobinuria Drug Market By Treatment (Medication, Supplements, Blood Transfusion, And Bone Marrow…

The first targeted C3 therapy approved in CanadaApproval based on results from head-to-head PEGASUS phase 3 study where Empaveli™ demonstrated superiority to eculizumab in improving hemoglobin levels1On trial, transfusion avoidance was…

EMPAVELI, the first targeted C3 therapy, is approved for use in adults with PNH who are:Treatment naïveSwitching from C5 inhibitor Soliris® (eculizumab) Switching from C5 inhibitor Ultomiris® (ravulizumab) EMPAVELI was superior to…